These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31376178)

  • 1. Psoriatic arthritis induced by anti-programmed death 1 antibody pembrolizumab.
    Hara T; Mikita N; Ikeda T; Inaba Y; Kunimoto K; Kaminaka C; Kanazawa N; Yamamoto Y; Jinnin M
    J Dermatol; 2019 Dec; 46(12):e466-e467. PubMed ID: 31376178
    [No Abstract]   [Full Text] [Related]  

  • 2. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
    Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
    J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
    Kurokawa K; Hara M; Iwakami SI; Genda T; Iwakami N; Miyashita Y; Fujioka M; Sasaki S; Takahashi K
    Intern Med; 2019; 58(22):3283-3287. PubMed ID: 31735738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab induced toxic epidermal necrolysis.
    Kumar R; Bhandari S
    Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
    [No Abstract]   [Full Text] [Related]  

  • 5. Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma.
    Hamada S; Fuseya Y; Tsukino M
    Arch Bronconeumol (Engl Ed); 2018 Jun; 54(6):346-348. PubMed ID: 29496287
    [No Abstract]   [Full Text] [Related]  

  • 6. Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab.
    Alberti A; Mancin M; Cortinovis D; Bidoli P; Sala L
    Immunotherapy; 2020 Jun; 12(9):629-633. PubMed ID: 32418466
    [No Abstract]   [Full Text] [Related]  

  • 7. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG
    Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740
    [No Abstract]   [Full Text] [Related]  

  • 8. Toxic epidermal necrolysis associated with pembrolizumab.
    Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case of dermatomyositis during treatment with pembrolizumab for lung cancer.
    Hinogami H; Yamashita C; Tanaka A; Shirai H; Nakano Y; Matsuura Y
    J Dermatol; 2019 Nov; 46(11):e430-e432. PubMed ID: 31215668
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
    Adachi E; Honda T; Nonoyama S; Irie H; Yamamura K; Otsuka A; Kabashima K
    J Dermatol; 2019 Jul; 46(7):e232-e233. PubMed ID: 30758879
    [No Abstract]   [Full Text] [Related]  

  • 11. Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
    Coscarart A; Martel J; Lee MP; Wang AR
    J Cutan Pathol; 2020 Mar; 47(3):275-279. PubMed ID: 31589773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalized morphea in the setting of pembrolizumab.
    Cheng MW; Hisaw LD; Bernet L
    Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
    [No Abstract]   [Full Text] [Related]  

  • 13. Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
    Harada K; Ogasawara M; Shido A; Meno A; Oda S; Yoshida S; Yoshida S; Yoshikawa A; Ebata K; Abiko S; Kawagishi N; Sano I; Oda H; Miyagishima T
    Thorac Cancer; 2020 May; 11(5):1350-1353. PubMed ID: 32181993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    Hsu CL; Chen KY; Kuo SW; Chang YL
    J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
    [No Abstract]   [Full Text] [Related]  

  • 15. Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung.
    Robinson SD; Lai C; Hotton G; Anand G
    Acute Med; 2019; 18(3):197-199. PubMed ID: 31536059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-induced vitiligo in a patient with lung adenocarcinoma: A case report.
    Bulat V; Likic R; Bradic L; Speeckaert R; Azdajic MD
    Br J Clin Pharmacol; 2021 Jun; 87(6):2614-2618. PubMed ID: 33217043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
    Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
    Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe polyradiculoneuritis associated with the combination of ipilimumab and pembrolizumab in a lung cancer patient.
    Cho HS; Lee KY; Hu CJ; Chung CC
    Neurol India; 2018; 66(2):509-511. PubMed ID: 29547174
    [No Abstract]   [Full Text] [Related]  

  • 19. Bilateral Vocal Cord Paralysis: Pembrolizumab-Induced Delayed-Onset Toxicity in a Patient with Lung Adenocarcinoma.
    Hamada S; Okamoto N; Tsukino M
    J Thorac Oncol; 2018 Dec; 13(12):e257-e259. PubMed ID: 30467049
    [No Abstract]   [Full Text] [Related]  

  • 20. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
    Goldstein DA; Bilal U; Prasad V
    Cancer; 2017 Oct; 123(20):3872-3874. PubMed ID: 28662268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.